The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Starnes, C. O.
Right arrow Articles by Levy, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Starnes, C. O.
Right arrow Articles by Levy, R.

The Journal of Immunology, Vol 141, Issue 1 333-339, Copyright © 1988 by American Association of Immunologists

ARTICLES

Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants

CO Starnes, WL Carroll, MJ Campbell, LL Houston, G Apell and R Levy
Department of Medicine, Stanford University Medical Center, CA 94305.

mAb directed toward the idiotype of the 38C13 murine B cell lymphoma can be used to treat and cure a high percentage of mice challenged previously with an otherwise lethal dose of tumor cells. Tumors developing in animals despite antibody therapy were examined by immunofluorescence and found to demonstrate either loss of surface Ig, or expression of an altered idiotype that no longer bound the antibody used for treatment. Further immunofluorescence analysis of the variant tumors revealed individual patterns of cross-reactivity with anti-38C13 idiotype mAb other than that used for therapy. The variant tumor cells were fused to myeloma cells and hybrids were isolated which secreted large quantities of the altered idiotype proteins. Polyclonal antibodies and mAb prepared against the mutant proteins demonstrated cross-reactivity with the original 38C13 protein and its other variants. But the variants and wild type cells could be distinguished from each other by their patterns of reactivity with the panels of anti- idiotype antibodies. Differences in apparent m.w. were demonstrated in the L chains of each of the mutant proteins. Southern blot analysis of the H chain locus of these mutants established that they were all clonally related; however, the L chain loci were grossly different. Thus, rare cells with alteration in their Ig L chain genes and expressed proteins can give rise to idiotype variants in this B cell tumor.


This article has been cited by other articles:


Home page
 BloodHome page
S. N. Franki, K. K. Steward, D. J. Betting, K. Kafi, R. E. Yamada, and J. M. Timmerman
Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo
Blood, February 1, 2008; 111(3): 1504 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. D. Syrengelas and R. Levy
DNA Vaccination Against the Idiotype of a Murine B Cell Lymphoma: Mechanism of Tumor Protection
J. Immunol., April 15, 1999; 162(8): 4790 - 4795.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S.-J. Liu, Y.-P. Sher, C.-C. Ting, K.-W. Liao, C.-P. Yu, and M.-H. Tao
Treatment of B-Cell Lymphoma With Chimeric IgG and Single-Chain Fv Antibody-Interleukin-2 Fusion Proteins
Blood, September 15, 1998; 92(6): 2103 - 2112.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Wooldridge, Z. Ballas, A. M. Krieg, and G. J. Weiner
Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma
Blood, April 15, 1997; 89(8): 2994 - 2998.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.